Peter H. O’Donnell

The repertoire of mutational signatures in human cancer

Mi Ni Huang, Alvin Wei Tian Ng, Arnoud Boot et al. · Nature · 2020 · 3.7K citations · Full text

Life Sciences, Genetics, Oncology +14

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles et al. · The Lancet · 2016 · 3.7K citations

Medicine, Oncology, Pharmacotherapy +13

Pan-cancer analysis of whole genomes

Lauri A. Aaltonen, Federico Abascal, Adam Abeshouse et al. · Nature · 2020 · 3.3K citations · Full text

Life Sciences, Genetics, Oncology +16

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

A. Gordon Robertson, Jaegil Kim, Hikmat Al‐Ahmadie et al. · Cell · 2017 · 2.5K citations · Full text

Medicine, Molecular Biology, Oncology +14

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell et al. · The Lancet Oncology · 2017 · 1.3K citations

Medicine, Oncology, Pharmacology +12